Could this be bigger than Humira - whose sales topped $9.3 Billion!
Humira, a treatment for rheumatoid arthritis, psoriasis, Crohn's disease and other conditions, is the world's top-selling prescription drug. Sales have risen steadily since it was introduced in 2002.
The Best Selling Drugs of All Time; Humira Joins The Elite
Comment Now Follow Comments
When Abbott announced its full-year results last week, its anti-TNF inhibitor product Humira delivered a stronger-than-expected 23.1 percent year-on-year increase in Q4 sales (recorded at $2.7 billion). Annual sales for 2012 stood at $9.3 billion, cementing the status of Humira as one of the biggest selling products of all time.
Measured in terms of peak annual sales, Humira revenues in 2012 were marginally below the combined sales of Plavix recorded by Bristol-Myers Squibb and Sanofi in 2011. However, while Plavix revenues are now undergoing a dramatic decline following US patent expiry last year, Humira continues to act as a key growth product for Abbott/AbbVie, and is expected to do so for some time.
Based on an annualised Q4 2012 performance, Humira sales would stand at $10.7 billion; thus full-year revenues for 2013 can be expected to easily outstrip those of Plavix and move closer to the peak $13.7 billion figure set by Pfizer‘s Lipitor.
The side effects of Humira are horrible. A safe alternative from IDRA could easily take a huge chunk of that market. Arthritis is a nasty, tortuous disease and relief from it would gladden tens of millions of people.